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Abstract: Indoleamine 2,3-dioxygenase (IDO) catalyzes the initial and rate-limiting step of tryptophan catabolism in a specific pathway, 
resulting in a series of extracellular messengers collectively known as kynurenines. IDO has been recognized as an authentic regulator of 
immunity not only in mammalian pregnancy, but also in infection, autoimmunity, inflammation, allergy, transplantation, and neoplasia. 
Its suppressive effects are mostly mediated by dendritic cells (DCs) and involve tryptophan deprivation and/or production of kynurenines, 
which act on IDO-negative DCs as well as CD4+ and CD8+ T cells. We have found that mouse IDO contains two tyrosine residues 
within two distinct putative immunoreceptor tyrosine-based inhibitory motifs, VPY115CEL and LLY253EGV. We have also found that 
Suppressor of Cytokine Signaling 3 (SOCS3)—known to interact with phosphotyrosine-containing peptides and be selectively induced 
by interleukin 6 (IL-6)—binds mouse IDO, recruits the ECS (Elongin-Cullin-SOCS) E3 ligase, and targets the IDO/SOCS3 complex 
for proteasomal degradation. This event underlies the ability of IL-6 to convert otherwise tolerogenic, IDO-competent DCs into immu-
nogenic cells. Thus onset of immunity in response to antigen within an early inflammatory context demands that IDO be degraded in 
tolerogenic DCs. These studies support the finding that IDO is regulated by proteasomal degradation in response to immunogenic and 
inflammatory stimuli.
Keywords: IL-6, SOCS proteins, tryptophan catabolism, dendritic cellspallotta et al
92  International Journal of Tryptophan Research 2010:3
Introduction
Suppressor  of  cytokine  signaling  (SOCS)  proteins 
have emerged as critical modulators of cytokine-medi-
ated processes.1 A series of studies with various exper-
imental approaches have demonstrated that SOCS3 
modulates interferon (IFN)-γ-inducible genes and is 
involved in the prevention of IFN-γ-like responses in 
hepatocytes and macrophages stimulated with inter-
leukin  (IL)-6.2–4  It  has  been  suggested  that,  in  the 
absence of SOCS3, IL-6 may become immunosup-
pressive, activating genes typically induced by IFNs.5 
Not only does the feedback inhibitor SOCS3 attenu-
ate IL-6 signaling,6 but also upregulation of SOCS3 
by IL-6 is responsible for inhibiting the IFN-γ–driven 
transcriptional expression of IDO.7 In fact, although 
SOCS3  may  be  an  important  regulator  of  IDO  in 
response to nitric oxide,8 an inducer of SOCS3,9 the 
underlying mechanisms could be broader than sim-
ply  opposing  IFN-γ  signaling  and  the  IFN-γ–like 
actions of IL-6.10 SOCS proteins are, in general, criti-
cal modulators of immune responses,11 and they pos-
sess an Src homology 2 (SH2) domain, which binds 
phosphotyrosine-containing  peptides,  and  a  SOCS 
box. The latter domain participates in the formation 
of an E3 ubiquitin ligase complex and targets several 
signaling  proteins  for  proteasomal  degradation.12–15 
In murine dendritic cells (DCs), treatment with IL-
6 up-regulates SOCS3 and prevents IDO activation 
by IFN-γ.7,16 We found an inverse correlation between 
SOCS3  and  IDO  expression.10,17,18  Not  only  does 
SOCS3  influence  IL-6  transcriptional  programs  in 
DCs, but it can also contribute to posttranscriptional 
events that directly shape the presentation pattern of 
DC subsets programmed to direct tolerance. In this 
study we demonstrate that IL-6 exerts immunogenic 
effects on otherwise tolerogenic CD8+ DCs that are 
contingent on functional SOCS3 in vivo and impaired 
tryptophan catabolism in vitro.
Materials and Methods
Mice and reagents
Eight- to ten-week-old female DBA/2J (H-2d) mice 
were obtained from Charles River Breeding Labora-
tories. All in vivo studies were conducted in compli-
ance  with  National  (Italian  Parliament  DL  116/92) 
and Perugia University Animal Care and Use Com-
mittee  guidelines.  Murine  rIL-6  was  from  Peprot-
ech.  Rabbit  monoclonal  anti-mouse  IDO  antibody 
(cv152)  was  obtained  as  described.19  Anti-SOCS3 
and  anti-Flag  M2  antibodies  were  purchased  from 
Abcam  and  Sigma-Aldrich,  respectively. Anti-ubiq-
uitin  was  from  Cell  Signaling. The  P815AB  tumor 
peptide  (amino  acid  sequence  LPYLGWLVF)  was 
synthesized  and  purified  as  described.20,21  Biotinyl-
ated  phosphorylated  and  unphosphorylated  pep-
tides  for  pull-down  experiments  spanning  the 
ITIM-contained  tyrosines  of  mouse  IDO  (ITIM1: 
SGSGNIAVPY115CELSE;  pITIM1:  SGSGNIAVP-
pY115CELSE;  ITIM2:  SGSGPEGLLY253EGVWD; 
pITIM2: SGSGPEGLLpY253 EGVWD) were obtained 
from Sigma-Genosys. The IDO inhibitor 1-MT (d,l-
isomers; Sigma-Aldrich) and the proteasome inhibitor 
MG132 (Calbiochem) were also used.
DC purification and treatments
Splenic DCs were purified using CD11c MicroBeads 
(Miltenyi Biotec) in the presence of EDTA to disrupt 
DC-T  cell  complexes.22  Cells  were  99%  CD11c+, 
99% MHC I-A+, 98% B7-2+, 0.1% CD3+, and 
appeared  to  consist  of  90%–95%  CD8–,  5%–10% 
CD8+, and 1%–5% B220+ cells. DC populations were 
further  fractionated  according  to  CD8  expression  in 
order to obtain purified CD8+ DCs by means of CD8α 
MicroBeads (Miltenyi Biotec). After cell fractionation, 
the CD8+ fraction was made up of 95% CD8+ DCs. 
Less than 1% CD8+ and 5% CD8– DCs expressed the 
B220 marker, respectively23 DCs were exposed to 20 
ng/ml rIL-6 for 24 h at 37 °C. Also used, in specific 
experiments, were 1-MT (4 µM) and MG132 (10 µM).
RT-pcR analysis
Expression of SOCS3 (sense, 5′-CAGCCTGCGCCT 
CAAGACCTT-3′; antisense, 5′-GCACCAGCTTGA 
GTACACAGTCG-3′) transcripts were evaluated by 
RT-PCR  analysis  using  specific  primers.  RT-PCR 
products were also normalized to murine Gapdh.
siRnA synthesis and transfection
These procedures have been described previously.10,24 
Briefly, the siRNA sequences specific for murine SOCS3 
(sense, 5′-GGAGCAAAAGGGUCAGAGGtt-3′; anti-
sense,  5′-CCUCUGACCCUUUUGCUCCtt-3′)  were 
selected, synthesized and annealed by the manufacturer 
(Ambion). For transfection, siRNAs (5 µg) in 30 µl of 
transfection buffer (20 mM HEPES, 150 mM NaCl, 
pH 7.4) were pipetted into a sterile Eppendorf tube. proteasomal degradation in dendritic cells
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In a separate polystyrene tube, 6.7 µg of 1,2 dioleoyl-
3-trimethylammonium-propane (DOTAP) was mixed 
with 30 µl of transfection buffer and then both solu-
tions  were  mixed  gently  by  pipetting  several  times. 
After incubation at room temperature for 20 min, the 
mixture was added to 1 ml of complete medium con-
taining 106 DCs and incubated for 24 h at 37 °C in the 
presence of rIL-6. Cells were then recovered, washed 
and immediately used for in vivo experiments. siRNA 
treatment  resulted  in  the  complete  disappearance  of 
SOCS3 transcripts at 24–48 h, as described.10,24 Control 
treatments consisted of cells treated with negative con-
trol siRNA (Ambion). After siRNA transfection, DC 
viability always exceeded 70%.
Construction and expression of mouse IDO-flag
Constructs  expressing  mouse  IDO  were  generated 
amplifying the cDNA from purified DCs (Indo gene) 
with primers (Table 1) containing SpeI (sense) and 
NotI  (antisense)  restriction  enzyme  site  sequences. 
The antisense primer also contained an N-terminal 
Flag-encoding sequence and a linker sequence cod-
ing for Gly3 to ensure flexibility of the resulting Flag-
tagged protein. PCR products were digested with the 
appropriate restriction enzymes and cloned into a pEF-
BOS plasmid. Since immunostimulatory sequences 
present in plasmid DNA (i.e. hypomethylated CpG 
motifs) may produce nonspecific effects, we trans-
fected DCs by means of mRNAs. Briefly, plasmids 
obtained as above were linearized, purified using a 
Geneprep kit (Ambion), and used as templates for 
the in vitro transcription reaction using the mMES-
SAGE mMACHINE T7 Ultra Kit (Ambion). Con-
centration and quality of in vitro-transcribed mRNAs 
were assessed by spectrophotometry and agarose gel 
electrophoresis. Control mRNA was obtained from 
the  pTRI-Xef  plasmid  (supplied  by  manufacturer) 
containing the Xenopus elongation factor 1α gene, 
which codes for a 50.2 kDa protein. One million DCs 
were transfected with 2 µg mRNA, using DOTAP as 
described above for siRNA transfection.7
Immunization and skin test assay
For immunization in vivo, fractionated DCs, either 
as  such  or  treated  and/or  transfected  as  described 
above, were loaded with the P815AB peptide in vitro 
(5 µM, 2 h at 37 °C), before intravenous injection into 
DBA/2J recipient hosts. Three × 105 peptide-loaded 
CD8+ DCs were injected. A skin test assay was used 
for measuring class I-restricted, delayed-type hyper-
sensitivity responses to synthetic peptides as previ-
ously  described.7,25  The  response  to  intrafootpad 
challenge with the eliciting peptide was measured at 
2 weeks, and results were expressed as the increase in 
footpad weight of peptide-injected footpads over that 
of respective, vehicle-injected counterparts.7 Data are 
the mean ± SD for at least six mice per group.
Kynurenine assay
IDO  functional  activity  was  measured  in  vitro  in 
terms of the ability of DCs to metabolize tryptophan 
to kynurenine, the concentrations of which were mea-
sured by HPLC as described previously.19,26
peptide pull-down experiments, 
Immunoprecipitation, and immunoblot analyses
Cells [2–5 × 105/sample for immunoblots of whole 
cell  lysates;  3  ×  106  DCs/sample  for  immunopre-
cipitation] were lysed on ice in RIPA buffer (50 mM 
Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 0.25% 
Na-deoxycholate,  1  mM  EDTA,  1.4  mM  Na3VO4, 
and protease inhibitors). Lysates were either immu-
noprecipitated with the anti-Flag antibody or directly 
run on SDS-PAGE. For pull-down experiments, cell 
lysates were incubated sequentially with 10 µg bioti-
nylated peptide (2 h) and streptavidin agarose beads 
(2 h). Immunoblots involved the use of specific anti-
bodies in combination with the appropriate horserad-
ish peroxidase conjugates, followed by ECL.
statistical analysis
Student’s t-test was used to analyze the results of in vitro 
studies in which data are mean values (± SD). In the in 
vivo skin test assay, statistical analysis was performed 
Table 1. primer sequences.
construct sense and antisense oligonucleotides
IDO s, 5′-ggccAAAcTAgTggTcAgTggAgTAgAcAgcA-3′  
As, 5′-TcTAgAgTcgcggccgcTTAcTTATcgTcATcgTcTTTgTAATcTccTccTccAggccAAc 
TcAgAAgAgcTT-3′pallotta et al
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using two-tailed paired t-test by comparing the mean 
weight of experimental footpads with that of control, 
saline  injected  counterparts.21  Data  are  mean  values 
(±SD) of three experiments with at least six mice per 
group per experiment, as computed by power analysis to 
yield a power of at least 80% with an α level of 0.05.27
Results and Discussion
sOcs3 is required for the effect of IL-6 
on cD8+ Dcs
Mouse splenic DCs can present peptide antigens in 
an immunogenic or tolerogenic way, with the distinc-
tion depending on either the occurrence of specialized 
DC subsets or the maturation or activation state of the 
DC.28 Environmental factors are crucial in condition-
ing the outcome of DC presentation of the synthetic 
tumor/self nonapeptide P815AB,21,29 a poorly immu-
nogenic antigen of mouse mastocytoma P1.HTR.30 DC 
populations in the spleens of DBA/2 mice consist of 
CD8− (~90%) and CD8+ (~10%) fractions that mediate 
the respective immunogenic and tolerogenic presen-
tation of the synthetic nonapeptide P815AB.31 Upon 
transfer into recipient hosts, peptide-loaded CD8– DCs 
initiate immunity, and CD8+ DCs initiate anergy when 
Ag-specific skin test reactivity is measured at 2 wk after 
cell  transfer.20,29  Consistent  with  previous  results  of 
adjuvant activity by IL-6,7 otherwise tolerogenic CD8+ 
DCs were made capable of immunogenic presentation 
of P815AB when exposed to IL-6 before peptide load-
ing and transfer into recipient hosts (Fig. 1A). IL-6 is 
a multifunctional cytokine that regulates inflammatory 
responses, and overproduction of IL-6 is associated 
with  autoimmunity  and  chronic  inflammatory  dis-
eases.5 It has been shown that IL-6 strongly activates 
STAT3 and induces the expression of IFN-responsive 
genes in SOCS3-deficient macrophages, indicating that 
IL-6 might mimic the actions of IFNs.2,3 We examined 
whether SOCS3 expression is required for IL-6 effects 
on CD8+ DCs. Splenic DCs were fractionated, and spe-
cific SOCS3 gene silencing was achieved in the CD8+ 
fraction with siRNA technology. P815AB-pulsed CD8+ 
DCs were injected either untreated or treated with rIL-
6, with or without concomitant siRNA-SOCS3 treat-
ment (Fig. 1A). The results showed that SOCS3 was an 
absolute requirement for the occurrence of regulatory 
effects by rIL-6 on CD8+ DCs. Thus, in the absence 
of SOCS3, CD8+ DCs are refractory to immunomodu-
lation by externally added IL-6, leaving their default 
tolerogenic program apparently unaffected. Also, the 
effect of IL-6 on SOCS3-deficient CD8+ cells was due 
to active suppression involving IDO because it could be 
reversed by the addition of the enzyme inhibitor 1-MT 
during  cell  exposure  to  the  cytokine  (Fig.  1A).  On 
analyzing IDO expression by Western blot using rab-
bit monoclonal IDO-specific Ab, we found increased 
detection of the enzyme protein after IL-6 treatment 
in cells lacking SOCS3 (Fig. 1B). This was reflected 
by enhanced conversion of tryptophan to kynurenine 
(Fig. 1C). Therefore, IL-6 strongly activates trypto-
phan catabolism in DCs with silenced expression of 
SOCS3. It is also of interest that IL-6 may increase 
SOCS3 transcriptional expression (Fig. 1D).
proteasome–mediated degradation  
of IDO
The mechanisms of action of SOCS proteins include 
SOCS box targeting of bound proteins to ubiquitin-
proteasome–mediated degradation. The  proteasome 
is a major protein-degrading enzyme, which catalyzes 
degradation  of  oxidized  and  aged  proteins,  signal 
transduction factors and cleaves peptides for antigen 
presentation. As mentioned above, 1-MT is a spe-
cific and widely used inhibitor of IDO activity,32 and 
MG132 is a specific proteasome inhibitor. We exam-
ined  the  inverse  relationship  between  SOCS3  and 
IDO functions by using the two inhibitors in combi-
nation. In a skin test assay with P815AB, CD8+ DCs 
rendered immunogenic by IL-6 (Fig. 2A) would revert 
their phenotype when co-treated with MG132, yet the 
addition of 1-MT restored immunogenicity. Studies 
of IDO function in vitro with CD8+ DCs treated with 
IL-6 confirmed that MG132 activated the metabolic 
conversion of tryptophan to kynurenine—the initial 
IDO-dependent catabolite—and it did so in a 1-MT–
sensitive manner (Fig. 2B). Therefore, an inverse rela-
tionship appeared to occur in DCs between functional 
IDO and SOCS3-proteasome–mediated effects.
SOCS3 binds IDO via specific 
phosphotyrosine binding and mediates 
ubiquitination and proteasomal 
degradation of IDO
SOCS3-associated  SH2  domains  bind  protein 
sequences shared by inhibitory receptors,12,33 i.e. ITIMs. 
A prototypic ITIM is the I/V/L/SxYxxL/V sequence,34 
where  x  denotes  any  amino  acid.  As  previously proteasomal degradation in dendritic cells
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Figure 1. IL-6 becomes immunosuppressive in Dcs lacking sOcs3, and modulation of sOcs3 by gene silencing enhances IDO expression, and trypto-
phan catabolism in response to IL-6. A) The effects of IL-6 on cD8+ Dcs require sOcs3. p815AB-pulsed cD8+ Dcs were transferred into recipient mice 
to be assayed for skin test reactivity at 2 wk. The cD8+ Dc fraction was used as such or after treatment with rIL-6, with or without concomitant SOCS3 
gene silencing by siRnA. control cells consisted of cD8+ treated with DOTAP alone. The effect of IL-6 on SOCS3-deficient cells was also studied in the 
presence of 1-MT treatment. *, P  0.001, experimental vs control footpads. B) cD8+ Dcs, either with control treatment c) or subjected to siRnA treat-
ment, were exposed to IL-6 and assayed for expression of IDO protein by Western blot analyses. c) IL-6 was studied for the ability to induce tryptophan 
conversion to kynurenine in cD8+ Dcs with or without concomitant Socs3 gene silencing by siRnA. Kynurenine levels in supernatants were measured by 
hpLc, and the results are the mean ± sD of triplicate samples in one of three experiments. control treatment (c) consisted of DOTAp alone. D) RT-pcR 
analysis of sOcs3 expression in cD8+ DCs treated with IL-6 for 2 h. Results are from one experiment representative of four. PCR bands were quantified 
by scanning densitometry and represented as fold change in IL-6 treated (2.5 ± 0.7, P = 0.045) relative to untreated control (in which fold change is 1).
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recognized by our studies, IDO contains two tyro-
sines  within  two  distinct  canonical  ITIMs  (ITIM1, 
VPY115CEL; ITIM2, LLY253EGV).18 The occurrence 
of ITIM domains in mouse IDO raised the possibil-
ity that the enzyme undergoes ubiquitin-proteasome–
mediated degradation after tyrosine phosphorylation 
and SOCS3 binding via SH2 domains with high affin-
ity for ITIM phosphotyrosine. To verify whether the 
putative ITIMs in IDO could represent docking sites 
for SOCS3, biotinylated peptides with phosphorylated 
or  unphosphorylated  mouse  IDO  ITIM1  or  ITIM2 
sequences were used in a pull-down assay of SOCS3. 
Lysates  from  IL-6–treated  DCs  were  treated  with 
unphosphorylated or phosphorylated IDO peptides and 
immunoblotted with anti-SOCS3 (Fig. 3A). We found 
that  SOCS3  is  associated  with  the  phosphorylated 
forms of IDO peptides. We investigated whether the 
SOCS3-dependent immunoadjuvant activity of IL-6 
in  DCs  is  associated  with  posttranslational  modifi-
cation and proteasomal degradation of IDO. Unfrac-
tionated DCs were transfected with IDO-Flag mRNA 
and treated with IL-6 in the presence or absence of 
MG132. Cells were lysed and IDO-Flag was immu-
noprecipitated with anti-Flag. Sequential immunob-
lotting  was  conducted  using  anti-ubiquitin  and  an 
IDO-specific monoclonal antibody. Aliquots of whole 
cell lysates from parallel samples were blotted with 
SOCS3- and β-tubulin-specific antibodies (Fig. 3B). 
Treatment of IDO-Flag–transfected in DCs with IL-6 
caused the appearance of several ubiquitinated pro-
teins (as detected by specific anti-ubiquitin antibody), 
immunoprecipitated by anti-Flag antibody, which were 
greater in size than the IDO-Flag protein (42 kDa). 
Interestingly,  the  bands  corresponding  to  ubiqui-
tinated proteins became more intense in DCs stimu-
lated with IL-6 in the presence of MG132. Moreover, 
SOCS3 expression also increased in cells treated with 
the combination of IL-6 and MG132, thus suggest-
ing that, in accordance with previous results,12,33 the 
SOCS3 protein itself is degraded by the proteasome 
concomitantly with its target protein.
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